EXICURE Confirms Emerging Growth Company Status
Ticker: XCUR · Form: 8-K · Filed: Feb 5, 2024 · CIK: 1698530
| Field | Detail |
|---|---|
| Company | Exicure, Inc. (XCUR) |
| Form Type | 8-K |
| Filed Date | Feb 5, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: regulatory-filing, emerging-growth-company, corporate-governance
TL;DR
**EXICURE is an 'emerging growth company,' meaning less SEC paperwork but also less public info for investors.**
AI Summary
EXICURE, INC. filed an 8-K on February 5, 2024, to disclose that it is an "emerging growth company" as defined by the SEC. This status allows the company to take advantage of reduced reporting requirements, which could save them money and administrative effort. For investors, this means less frequent or detailed disclosures compared to larger, more established companies, which might impact the transparency of their investment.
Why It Matters
This filing confirms EXICURE's status as an emerging growth company, which means it benefits from relaxed SEC reporting rules. While this can reduce compliance costs for the company, it also means investors might have access to less frequent or detailed information.
Risk Assessment
Risk Level: low — This filing is purely administrative, confirming a status that has been in place, and does not introduce new financial or operational risks.
Analyst Insight
Investors should be aware that EXICURE, INC.'s 'emerging growth company' status means they might receive less frequent or detailed financial information compared to non-EGCs, and should factor this into their due diligence.
Key Players & Entities
- EXICURE, INC. (company) — the registrant filing the 8-K
- February 5, 2024 (date) — date of earliest event reported and filing date
- Nasdaq Stock Market LLC (company) — exchange where EXICURE's Common Stock is registered
- XCUR (company) — trading symbol for EXICURE, INC.
Forward-Looking Statements
- EXICURE, INC. will continue to benefit from reduced SEC reporting requirements. (EXICURE, INC.) — high confidence, target: 2025-02-05
FAQ
What is the purpose of EXICURE, INC.'s 8-K filing on February 5, 2024?
The 8-K filing by EXICURE, INC. on February 5, 2024, serves to indicate whether the registrant is an "emerging growth company" as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. The filing explicitly checks the box confirming it is an emerging growth company.
What is EXICURE, INC.'s trading symbol and on which exchange is its common stock registered?
EXICURE, INC.'s trading symbol is XCUR, and its Common Stock, par value $0.0001 per share, is registered on The Nasdaq Stock Market LLC.
What is the state of incorporation for EXICURE, INC. and its business address?
EXICURE, INC. is incorporated in Delaware, and its principal executive offices are located at 2430 N. Halsted St., Chicago, IL 60614.
What is the significance of EXICURE, INC. being an 'emerging growth company'?
Being an 'emerging growth company' allows EXICURE, INC. to take advantage of certain scaled-back disclosure requirements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as specified in the JOBS Act. This typically means reduced compliance costs and administrative burden for the company.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on February 5, 2024, which is also the date the report was filed.
Filing Stats: 408 words · 2 min read · ~1 pages · Grade level 11.2 · Accepted 2024-02-05 16:16:37
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share XCUR The Nasdaq Stock Market
Filing Documents
- xcur-20240205.htm (8-K) — 24KB
- a8kbluejay-exhibit991.htm (EX-99.1) — 9KB
- exicureimage1a10.gif (GRAPHIC) — 3KB
- 0001628280-24-003304.txt ( ) — 161KB
- xcur-20240205.xsd (EX-101.SCH) — 2KB
- xcur-20240205_lab.xml (EX-101.LAB) — 23KB
- xcur-20240205_pre.xml (EX-101.PRE) — 12KB
- xcur-20240205_htm.xml (XML) — 3KB
01 Other Regulation FD Disclosure
Item 7.01 Other Regulation FD Disclosure On February 5, 2024, the Company issued a press release regarding the licensing of certain patents to another therapeutic company for further development, which is attached hereto as Exhibit 99.1.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits Exhibit No. Description 99.1 Press release dated February 5, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: February 5, 2024 EXICURE, INC. By: /s/ Paul Kang Paul Kang Chief Executive Officer